Pay in 4 interest-free payments of $5.47 Learn more
Ships within 48 hours · Estimated delivery Oct 3 - Oct 8
Canada: The Canadian patent (CA 2,675,150) expires December 2028, with no patent term extension granted
According to the manufacturer's announcement, Novo Nordisk has described a limited-time savings offer for the starting dose at approximately $149 per month, subject to eligibility and change
This has significant implications on the risk profile of GLP-1 agonists in the perioperative setting
For prescription fills exceeding 30 days, we assumed supply extended across subsequent months (e.g., a 60-day fill was counted as two months of supply), referred to as active supply. Patients were required to have at least two consecutive months of active supply
US$ 26.63
US$ 28.98
US$ 28.43
US$ 29.68
